| First Author | Gallo-Hendrikx E | Year | 1994 |
| Journal | Oncogene | Volume | 9 |
| Issue | 10 | Pages | 2983-90 |
| PubMed ID | 8084602 | Mgi Jnum | J:20545 |
| Mgi Id | MGI:68631 | Citation | Gallo-Hendrikx E, et al. (1994) Enhancement of pancreatic tumor metastasis in transgenic immunodeficient mice. Oncogene 9(10):2983-90 |
| abstractText | Metastatic pancreatic cancer presents a bleak prognosis. Typically, human tumor development has been modelled in animals by generating transgenic mice carrying an oncogene, and metastasis studied by engrafting human tumor cells into immunodeficient mice. We derived mouse lines that spontaneously develop metastatic pancreatic cancer by crossing a transgenic line that develops primary pancreatic adenocarcinomas with lines that are deficient for different lymphocyte components of the immune system. We obtained transgenics carrying the SCID mutation resulting in loss of B and T cell function, those carrying the beige mutation resulting in impaired NK cell and macrophage activity, and those carrying both mutations. Although human graft studies indicated that the SCID mutation permits metastasis of different types of tumor cells, in our mice its effect on metastasis of the pancreatic tumor was minimal. In contrast, the beige mutation resulted in metastasis in almost 90% of the animals. The SCID and beige mutations synergistically resulted in faster growing tumors. Both primary tumors and metastases contained undifferentiated and differentiated cell types. The tissue distribution of metastases was similar to that recorded from human patients with pancreatic cancer, suggesting that mechanisms underlying metastasis in these mice could be similar to those involved in human disease. |
